• CCCP in Mitochondrial Research: Evidence and Limits

  2026-10-05

  CCCP, or carbonyl cyanide m-chlorophenyl hydrazine, is best understood as a mechanistic perturbation tool for studying proton motive force and oxidative phosphorylation rather than as a disease-specific reagent. This overview compares the mechanistic rationale for CCCP with findings from a 2025 study using urine-derived stem-cell mitochondrial morphology and deep learning to investigate Alzheimer’s disease, while distinguishing reported evidence from proposed applications and highlighting limits on clinical interpretation.

• Fluoxetine HCl and the Motivation Circuit

  2026-10-05

  Fluoxetine HCl is more than a serotonin transporter probe. When paired with developmental models and reward-focused behavioral readouts, it can help translational researchers distinguish serotonergic signaling, motivation, and downstream mu opioid circuit adaptations.

• Erastin Through the Lens of Cell Death Evidence

  2026-10-04

  Erastin is a widely used ferroptosis inducer for studying redox collapse in genetically defined tumor models. This article offers a cross-pathway framework that distinguishes ferroptosis from necroptosis and explains what the Liu et al. viral-immunity study contributes to cancer biology research.

• Oncostatin M in Fibrosis Research: Evidence and Limits

  2026-10-03

  Recombinant Human Oncostatin M is a context-dependent cytokine research tool with reported effects on fibroblast proliferation and cytokine release. Current supplied evidence supports a mast cell–tryptase–PAR2 mechanism in experimental peritoneal fibrosis, but does not directly establish a role for OSM in that pathway or support clinical extrapolation.

• Lipo3K Transfection Reagent for ASO Assays

  2026-10-02

  Discover how the Lipo3K Transfection Reagent can support controlled nucleic acid delivery in gene expression studies and RNA interference research. This guide connects lipid-mediated uptake with pH-responsive antisense oligonucleotide design, emphasizing assay controls, interpretation, and practical optimization.

• Erastin: Designing Better Ferroptosis Assays

  2026-10-01

  Erastin is a benchmark ferroptosis inducer for studying redox collapse in RAS/BRAF-associated cancer models. This article presents an assay-design framework that connects Erastin perturbation with acidic tumor biology, iron mobilization, lipid peroxidation, and radiation-response experiments.

• IWR-1-endo: Wnt Signaling Inhibitor Workflows

  2026-10-01

  Build reproducible Wnt/β-catenin experiments with IWR-1-endo, from DMSO stock preparation and dose–response design to orthogonal pathway and morphology readouts. The workflow also adapts high-content profiling concepts from cardiomyopathy research to strengthen colorectal cancer, stem-cell, and regeneration assays.

• Acetylcysteine for ROS and Pyroptosis Assays

  2026-09-30

  Acetylcysteine provides a practical redox-perturbation tool for testing whether photodynamic therapy damage depends on ROS rather than nonspecific toxicity. This workflow translates a breast cancer pyroptosis study into reproducible assay controls, concentration screens, and troubleshooting decisions.

• Triacetin for Metabolic–Epigenetic Assay Design

  2026-09-30

  Triacetin is more than a short-chain triglyceride: its hydrolysis, metabolic signaling, and context-dependent cytotoxicity can shape assay interpretation. This guide combines Triacetin biology with lessons from an epigenetic immuno-oncology study to develop better controls, readouts, and translational boundaries.

• Topotecan HCl Workflows for DNA Damage Studies

  2026-09-29

  Topotecan HCl provides a controllable topoisomerase 1 inhibitor workflow for linking replication-associated DNA damage with cytotoxicity, apoptosis, and treatment resistance. This guide combines cancer-model applications with a carefully bounded neuroinflammation connection inspired by recent CUX2 neuron-loss research.

• 3X (DYKDDDDK) Peptide: Workflow Guide

  2026-09-29

  The 3X (DYKDDDDK) Peptide combines a compact, hydrophilic epitope with three recognition repeats for sensitive capture, elution, and detection of recombinant proteins. This guide connects routine FLAG workflows with structural biology, metal-sensitive assays, and the Nsp1–NXF1/NXT1 host-pathogen mechanism.

• MK 0893: From Receptor Mechanism to Translation

  2026-09-28

  MK 0893 is a competitive, reversible glucagon receptor antagonist that connects allosteric receptor biology with cAMP pharmacology, animal-model validation, and translational strategy for type 2 diabetes research.

• Bivalent mRNA–LNP Vaccine Protects Chickens from H5/H7

  2026-09-28

  Wei and colleagues evaluated a nucleoside-modified mRNA–LNP vaccine encoding H5N1 and H7N9 hemagglutinins in SPF chickens. The study reports dose-dependent antibody responses, protection at the tested high doses against several homologous and heterologous challenges, and reduced viral replication and shedding—promising results that still require validation beyond the SPF model.

• Nifedipine and PXR: Separating Assay Questions

  2026-09-27

  Nifedipine (BAY-a-1040) is an L-type calcium-channel tool, not a PXR probe. This article explains how to keep calcium signaling experiments distinct from evidence on PXR-driven liver regeneration and CYP activity—and how that distinction improves assay interpretation.

• Meropenem Research Workflows for Resistance Studies

  2026-09-26

  Build a reproducible Meropenem workflow that connects susceptibility phenotypes with resistance-genotype and infection-model questions. Practical assay starting points, formulation cautions, and clear limits help distinguish broad-spectrum activity from activity against carbapenem-resistant isolates.

8091 records 3/540 page Previous Next 12345 下5页 Last page